A federal grand jury indicted a Utah stem cell clinic this month for distributing what prosecutors called "pop peptides" without authorization. The clinic's marketing had leaned heavily on the word "peptide," a word that also describes semaglutide, insulin, and over 100 other FDA-approved drugs. That borrowed credibility is the entire business model of the wellness peptide industry, and it is getting people hurt.
The legitimate peptide story is genuinely exciting. Retatrutide, Eli Lilly's GLP-1 peptide in development, achieved roughly 27% total body mass weight loss in trials, though a 20% dropout rate from side effects should temper the enthusiasm. On April 13, University of Birmingham researchers published preclinical data in Arthritis & Rheumatology showing that synthetic PEPITEM, a natural immunopeptide, reduced arthritic joint swelling in mouse models comparably to infliximab. Professor Helen McGettrick noted the "extremely low" toxicity risk. Neuland Laboratories just committed $30 million to a peptide manufacturing facility in Hyderabad. Real money follows real science.
But here is where the story splits. None of that evidence applies to BPC-157, TB-500, or the growth hormone secretagogues being sold through wellness clinics and gray-market websites. Zero FDA approvals for anti-aging, energy boosting, or athletic performance enhancement exist for any peptide. Not one.
The Mouse Study Problem
I will grant this: some unregulated peptides have interesting preclinical signals. BPC-157 has shown wound-healing effects in rodent models. That PEPITEM arthritis data from Birmingham is genuinely promising. But preclinical means mice, not humans. The distance between "reduced swelling in a mouse joint" and "safe and effective in a 72-kilogram human" is measured in years of clinical trials, billions of dollars, and a failure rate above 90%. Eric Topol has called the broader peptide craze "unfounded," and the evidence base for off-label use "wanting." Endocrinologist Esraa Askar at Stony Brook has been equally direct: solid human evidence is mostly lacking.
The people selling you BPC-157 know this. They just don't care.
What they care about is the halo effect. Semaglutide works. Insulin works. So "peptides" must work. Dr. Caplan at the CED Clinic put it precisely: "Lumping GLP-1 receptor agonists together with unregulated research compounds does a disservice to the science and to patients." The conflation is not accidental. It is the marketing strategy.
No Purity, No Dosing, No Recourse
Gray-market peptides have no purity standards. A vial labeled BPC-157 could contain the stated compound at the stated concentration, or it could contain degraded fragments, bacterial endotoxins, or nothing at all. You have no way to know. There is no certificate of analysis from an FDA-inspected facility. There is no established human dose because no human dose-finding study has been completed. You are injecting a substance whose identity you cannot verify, at a dose nobody has validated, for an indication nobody has tested in a controlled trial.
I understand the appeal of self-experimentation. Kai Brighton would call it "informed self-optimization," and I respect the impulse to take agency over your own biology. But informed consent requires information, and the information does not exist yet. You cannot make a rational risk-benefit calculation when the numerator and denominator are both unknown. That is not conservative caution. That is arithmetic.
Peptide researcher Conda Sheridan has stated it plainly: without FDA approval, a peptide has not shown beneficial effects in humans. Not "might not have." Has not.
The fix is straightforward. Clinicians need to stop prescribing unregulated peptides off formulary and start educating patients about the evidence gap. The FDA needs to treat gray-market peptide vendors the way it treats any other entity distributing unapproved drugs. And patients need to ask the question that protects them better than any supplement: "Show me the human trial."
The Utah clinic got indicted. Dozens of others are still open, still borrowing semaglutide's name to sell you a vial of hope with no data sheet attached.
